{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:22Z","timestamp":1791994582413,"version":"4.4.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jaad.2024.08.033","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:15:47Z","timestamp":1724458547000},"page":"1113-1117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of low-dose interleukin 2 in the treatment of moderate-to-severe bullous pemphigoid: A single center perspective-controlled trial"],"prefix":"10.1016","volume":"91","author":[{"given":"Ruzeng","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guomin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bocheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peizhen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyun","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk M.","family":"Elston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunsheng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2024.08.033_bib1","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/bjd.20743","article-title":"The global incidence of bullous pemphigoid: a systematic review and meta-analysis","volume":"186","author":"Persson","year":"2022","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.08.033_bib2","first-page":"516","article-title":"S2k guidelines for the treatment of pemphigus vulgaris\/foliaceus and bullous pemphigoid: 2019 update","volume":"18","author":"Schmidt","year":"2020","journal-title":"J Dtsche Dermatol Ges"},{"issue":"6","key":"10.1016\/j.jaad.2024.08.033_bib3","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.jaci.2018.03.014","article-title":"Regulatory T-cell dysfunction induces autoantibodies to bullous pemphigoid antigens in mice and human subjects","volume":"142","author":"Muramatsu","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.jaad.2024.08.033_bib4","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.jaci.2018.04.006","article-title":"Regulatory T-cell deficiency leads to pathogenic bullous pemphigoid antigen 230 autoantibody and autoimmune bullous disease","volume":"142","author":"Haeberle","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.jaad.2024.08.033_bib5","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/jdv.12091","article-title":"Regulatory T cells in skin lesions and blood of patients with bullous pemphigoid","volume":"28","author":"Antiga","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2024.08.033_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.jaad.2024.08.033_bib7","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2024.08.033_bib8","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/bjd.19611","article-title":"International validation of the bullous pemphigoid disease area index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid","volume":"184","author":"Masmoudi","year":"2021","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.08.033_bib9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2024.08.033_bib10","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1136\/ard-2022-222501","article-title":"Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial","volume":"81","author":"Humrich","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.jaad.2024.08.033_bib11","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jamadermatol.2014.504","article-title":"Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata","volume":"150","author":"Castela","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2024.08.033_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103156","article-title":"Short-term and low-dose IL-2 therapy increases the reduced Treg cells in patients with microscopic polyangiitis","volume":"21","author":"Wu","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"22","key":"10.1016\/j.jaad.2024.08.033_bib13","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis","volume":"365","author":"Saadoun","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jaad.2024.08.033_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cells11060980","article-title":"T cells, interleukin-2 and Systemic Lupus Erythematosus-From Pathophysiology to Therapy","volume":"11","author":"Mak","year":"2022","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.jaad.2024.08.033_bib15","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41584-021-00707-x","article-title":"Interleukin-2 and regulatory T cells in rheumatic diseases","volume":"17","author":"Kolios","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.08.033_bib16","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","article-title":"Autoimmunity and organ damage in systemic lupus erythematosus","volume":"21","author":"Tsokos","year":"2020","journal-title":"Nat Immunol"},{"issue":"8","key":"10.1016\/j.jaad.2024.08.033_bib17","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1016\/j.transproceed.2009.08.043","article-title":"Inhibitory effects of cyclosporine on human regulatory T cells in\u00a0vitro","volume":"41","author":"Miroux","year":"2009","journal-title":"Transplant Proc"},{"issue":"9","key":"10.1016\/j.jaad.2024.08.033_bib18","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jaad.2024.08.033_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaad.2024.08.033_bib20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cytogfr.2022.06.003","article-title":"Emerging mechanisms and applications of low-dose IL-2 therapy in autoimmunity","volume":"67","author":"Zhou","year":"2022","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"10.1016\/j.jaad.2024.08.033_bib21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","article-title":"Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial","volume":"1","author":"Hartemann","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"179","key":"10.1016\/j.jaad.2024.08.033_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005265","article-title":"Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease","volume":"5","author":"Matsuoka","year":"2013","journal-title":"Sci Transl Med"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224027300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224027300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T03:01:16Z","timestamp":1732071676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962224027300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0190962224027300"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2024.08.033","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of low-dose interleukin 2 in the treatment of moderate-to-severe bullous pemphigoid: A single center perspective-controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2024.08.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}